Verrica Pharmaceuticals
VRCA
51 hedge funds and large institutions have $72.1M invested in Verrica Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
13% more funds holding
Funds holding: 45 → 51 (+6)
0.02% less ownership
Funds ownership: 3.25% → 3.23% (-0.02%)
12% less capital invested
Capital invested by funds: $82M → $72.1M (-$9.93M)
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$244K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$226K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$202K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$93.1K |
| 5 |
Goldman Sachs
New York
|
+$89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.07M |
| 2 |
JP Morgan Chase
New York
|
-$125K |
| 3 |
BlackRock
New York
|
-$121K |
| 4 |
Barclays
London,
United Kingdom
|
-$113K |
| 5 |
PP
PDT Partners
New York
|
-$99K |
VRCA Hedge Fund Activity: Q1 2022 in Review
51 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2022, worth a combined $72.1M — down 12% from $82M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new VRCA positions and 4 closed out — a net gain of 6 holders — while 9 added to existing stakes and 18 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $244K. The largest seller was Morgan Stanley, cutting an estimated $1.07M.
- 51 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2022, up from 45 in Q4 2021.
- Funds reported $72.1M of Verrica Pharmaceuticals stock for Q1 2022, down 12% quarter-over-quarter.
- 10 funds opened new Verrica Pharmaceuticals positions in Q1 2022 and 4 closed out, a net change of +6 holders.
- The largest Verrica Pharmaceuticals buyer in Q1 2022 was Citadel Advisors, an estimated $244K added.
- The largest Verrica Pharmaceuticals seller in Q1 2022 was Morgan Stanley, an estimated $1.07M sold.
Based on aggregated 13F filings for Q1 2022.